Education
About Us
Working with TipRanks
Follow Us
MVAL - ETF AI Analysis
Top Page
VanEck Morningstar Wide Moat Value ETF (MVAL)
Rating:71Outperform
Price Target:―
Positive Factors
Strong Sector Diversification
The ETF is spread across multiple sectors, with significant exposure to Health Care, Consumer Defensive, and Industrials, reducing reliance on any single industry.
Reasonable Expense Ratio
The fund charges a moderate expense ratio compared to actively managed ETFs, helping investors retain more of their returns.
Consistent Performance
The ETF has shown steady gains year-to-date and over the past three months, indicating solid overall momentum.
Negative Factors
Weak Top Holdings Performance
Several top holdings, including Merck, Nike, and United Parcel, have underperformed year-to-date, dragging on the fund's potential growth.
High Geographic Concentration
The ETF is heavily focused on U.S. companies, offering little exposure to international markets and limiting global diversification.
Overweight in Health Care
With over 32% of the portfolio in Health Care, the fund is highly exposed to risks specific to this sector.
MVAL vs. SPDR S&P 500 ETF (SPY)
AUM5.45M
RegionNorth America
Expense Ratio0.49%
Beta0.73
IssuerVanEck
Inception DateMar 26, 2024
Dividend YieldN/A
Asset ClassEquity
Index TrackedMorningstar US Broad Value Wide Moat Focus Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume701
30 Day Avg. Volume289
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
40.95Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering39
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MVAL Summary
The VanEck Morningstar Wide Moat Value ETF (MVAL) is an investment fund that focuses on U.S. companies with strong competitive advantages, often called 'wide moats.' It follows the Morningstar US Broad Value Wide Moat Focus Index and includes well-known names like Nike and Thermo Fisher. This ETF is designed for investors seeking long-term growth by investing in undervalued, high-quality companies across sectors like healthcare, consumer goods, and technology. It offers diversification and a disciplined approach to finding strong businesses. However, new investors should know that its performance can fluctuate with the overall market, especially since it heavily focuses on U.S. stocks.
How much will it cost me?The VanEck Morningstar Wide Moat Value ETF (MVAL) has an expense ratio of 0.49%, which means you’ll pay $4.90 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed, focusing on selecting companies with strong competitive advantages. Active management typically involves more research and analysis, which can lead to higher costs.
What would affect this ETF?The VanEck Morningstar Wide Moat Value ETF (MVAL) could benefit from long-term growth in sectors like Health Care and Consumer Defensive, which are its largest exposures and tend to perform well during economic uncertainty. However, rising interest rates or economic slowdowns could negatively impact industrial and cyclical sectors, which also make up a significant portion of the ETF's holdings. Regulatory changes or competitive pressures affecting top holdings like Thermo Fisher or Nike may also influence the ETF's performance.
MVAL Top 10 Holdings
The VanEck Morningstar Wide Moat Value ETF (MVAL) leans heavily on healthcare and industrials, with names like Merck and Boeing helping to lift the fund thanks to steady growth and strategic initiatives. Estee Lauder has been a bright spot, showing signs of recovery with strong cash flow, while UPS and Zimmer Biomet have been lagging, weighed down by revenue challenges and bearish trends. With a clear U.S. focus and a tilt toward undervalued leaders, the fund’s performance is a mixed bag, but its emphasis on wide-moat companies offers long-term potential.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Merck & Company | 4.88% | $270.90K | $264.21B | 6.59% | 80 Outperform | |
| United Parcel | 4.68% | $259.79K | $85.40B | -20.34% | 72 Outperform | |
| Bristol-Myers Squibb | 4.66% | $259.19K | $111.38B | -5.67% | 78 Outperform | |
| Danaher | 4.62% | $256.45K | $163.50B | 0.08% | 75 Outperform | |
| Boeing | 4.11% | $228.56K | $170.83B | 20.94% | 54 Neutral | |
| Kenvue, Inc. | 4.07% | $226.28K | $32.97B | -21.64% | 73 Outperform | |
| Constellation Brands | 4.05% | $225.13K | $24.45B | -37.36% | 67 Neutral | |
| Zimmer Biomet Holdings | 3.83% | $212.75K | $17.88B | -15.87% | 73 Outperform | |
| Campbell Soup | 3.60% | $200.26K | $8.35B | -32.84% | 60 Neutral | |
| The Estée Lauder Companies | 3.36% | $186.43K | $38.73B | 43.31% | 56 Neutral |
MVAL Technical Analysis
Positive
―
Price Trends
35.23
Positive
34.52
Positive
32.81
Positive
Market Momentum
0.37
Positive
61.84
Neutral
9.76
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MVAL, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 36.17, equal to the 50-day MA of 35.23, and equal to the 200-day MA of 32.81, indicating a bullish trend. The MACD of 0.37 indicates Positive momentum. The RSI at 61.84 is Neutral, neither overbought nor oversold. The STOCH value of 9.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MVAL.
MVAL Peer Comparison
Comparison Results
Performance Comparison
MVAL
VanEck Morningstar Wide Moat Value ETF
36.56
4.48
13.97%
BAMV
Brookstone Value Stock ETF
―
―
―
TCV
Towle Value ETF
―
―
―
GMOV
GMO US Value ETF
―
―
―
CVAR
Cultivar ETF
―
―
―
NXTI
Simplify Next Intangible Core Index ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents